Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagida Bibi

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Nature Communications|August 21, 2023
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection historyHailey Hornsby, Alexander R Nicols, Stephanie Longet, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Nature Medicine|December 18, 2020
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Cell|March 17, 2021
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraDaming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, et al.
Wellcome Open Research|December 8, 2020
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virusMonique I Andersson, Carolina V Arancibia-Carcamo, Kathryn Auckland, et al.
Nature Medicine|December 18, 2020
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Cell|March 21, 2021
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine seraPiyada Supasa, Daming Zhou, Wanwisa Dejnirattisai, et al.
Cell|April 14, 2021
Antibody evasion by the P.1 strain of SARS-CoV-2Wanwisa Dejnirattisai, Daming Zhou, Piyada Supasa, et al.
Nature Medicine|May 7, 2021
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Nature Communications|August 21, 2023
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection historyHailey Hornsby, Alexander R Nicols, Stephanie Longet, et al.
Nature Medicine|May 22, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Nature Medicine|December 18, 2020
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, et al.
Cell|March 17, 2021
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraDaming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, et al.
Wellcome Open Research|December 8, 2020
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virusMonique I Andersson, Carolina V Arancibia-Carcamo, Kathryn Auckland, et al.
Nature Medicine|December 18, 2020
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Cell|March 21, 2021
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine seraPiyada Supasa, Daming Zhou, Wanwisa Dejnirattisai, et al.
Cell|April 14, 2021
Antibody evasion by the P.1 strain of SARS-CoV-2Wanwisa Dejnirattisai, Daming Zhou, Piyada Supasa, et al.
Nature Medicine|May 7, 2021
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Pageof 6